S5A), in particular, the two most common neuroblastoma predisposition genes, ALK and PHOX2B, and the cancer gene MYCN, somatic amplification of which is a key adverse marker used clinically for neuroblastoma risk stratification. Here, MYCN is linked to neuroblastoma.